Panitumumab outcome by tumour location analysis
Conclusions ‒ prognostic
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
In both 1
st
- and 2
nd
-line settings, mCRC patients with right-sided primary
tumours have worse prognosis, regardless of treatment received
In the 2
nd
-line setting, patients with right-sided tumours have very
poor prognosis
BRAF
mutations were observed in < 5% of left-sided vs
30% of right-
sided tumours
Patients with right-sided primary tumours still had worse prognosis after
adjusting for
BRAF
mutation status
The role of further biomarkers needs to be clarified
